Leishmaniasis and Chagas Disease – Neglected Tropical Diseases: Treatment Updates

Author(s): Leandro Stefano Sangenito, Vanessa da Silva Santos, Claudia Masini d'Avila-Levy, Marta Helena Branquinha, André Luis Souza dos Santos*, Simone S.C. de Oliveira.

Journal Name: Current Topics in Medicinal Chemistry

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer

[1]
WHO 2019 . https://www.who.int/neglected_diseases/diseases/en/ [(Accessed January 23, 2019)]
[2]
Fitzpatrick, C.; Nwankwo, U.; Lenk, E.; de Vlas, S.J.; Bundy, D.A.P. Major Infect.Dis. (3rd ed.); , 2017.
[3]
Charlton, R.L.; Rossi-Bergmann, B.; Denny, P.W.; Steel, P.G. Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. Parasitology, 2018, 145(2), 219-236. [http://dx.doi.org/10.1017/S0031182017000993]. [PMID: 28805165].
[4]
Sales, Junior, P.A.; Molina, I.; Fonseca Murta, S.M.; Sánchez-Montalvá, A.; Salvador, F.; Corrêa-Oliveira, R.; Carneiro, C.M. Experimental and clinical treatment of chagas disease: a review. Am. J. Trop. Med. Hyg., 2017, 97(5), 1289-1303. [http://dx.doi.org/10.4269/ajtmh.16-0761]. [PMID: 29016289].
[5]
Alcântara, L.M.; Ferreira, T.C.S.; Gadelha, F.R.; Miguel, D.C. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Int. J. Parasitol. Drugs Drug Resist., 2018, 8(3), 430-439. [http://dx.doi.org/10.1016/j.ijpddr.2018.09.006]. [PMID: 30293058].
[6]
Goyal, V.; Mahajan, R.; Pandey, K.; Singh, S.N.; Singh, R.S.; Strub-Wourgaft, N.; Alves, F.; Rabi Das, V.N.; Topno, R.K.; Sharma, B.; Balasegaram, M.; Bern, C.; Hightower, A.; Rijal, S.; Ellis, S.; Sunyoto, T.; Burza, S.; Lima, N.; Das, P.; Alvar, J. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Negl. Trop. Dis., 2018, 12(10), e0006830. [http://dx.doi.org/10.1371/journal.pntd.0006830]. [PMID: 30346949].
[7]
Rahman, R.; Goyal, V.; Haque, R.; Jamil, K.; Faiz, A.; Samad, R.; Ellis, S.; Balasegaram, M.; Boer, M.D.; Rijal, S.; Strub-Wourgaft, N.; Alves, F.; Alvar, J.; Sharma, B. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl. Trop. Dis., 2017, 11(5), e0005635. [http://dx.doi.org/10.1371/journal.pntd.0005635]. [PMID: 28558062].
[8]
Diro, E.; Blesson, S.; Edwards, T.; Ritmeijer, K.; Fikre, H.; Admassu, H.; Kibret, A.; Ellis, S.J.; Bardonneau, C.; Zijlstra, E.E.; Soipei, P.; Mutinda, B.; Omollo, R.; Kimutai, R.; Omwalo, G.; Wasunna, M.; Tadesse, F.; Alves, F.; Strub-Wourgaft, N.; Hailu, A.; Alexander, N.; Alvar, J. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl. Trop. Dis., 2019, 13(1), e0006988. [http://dx.doi.org/10.1371/journal.pntd.0006988]. [PMID: 30653490].
[9]
López, L.; Vélez, I.; Asela, C.; Cruz, C.; Alves, F.; Robledo, S.; Arana, B. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. PLoS Negl. Trop. Dis., 2018, 12(7), e0006653. [http://dx.doi.org/10.1371/journal.pntd.0006653]. [PMID: 30044792].
[10]
Soto, J.; Soto, P.; Ajata, A.; Luque, C.; Tintaya, C.; Paz, D.; Rivero, D.; Berman, J. Topical 15% paromomycin-aquaphilic for bolivian Leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial. Clin. Infect. Dis., 2019, 68(5), 844-849. [http://dx.doi.org/10.1093/cid/ciy619]. [PMID: 30260376].
[11]
Ben Salah, A.; Ben Messaoud, N.; Guedri, E.; Zaatour, A.; Ben Alaya, N.; Bettaieb, J.; Gharbi, A.; Belhadj Hamida, N.; Boukthir, A.; Chlif, S.; Abdelhamid, K.; El Ahmadi, Z.; Louzir, H.; Mokni, M.; Morizot, G.; Buffet, P.; Smith, P.L.; Kopydlowski, K.M.; Kreishman-Deitrick, M.; Smith, K.S.; Nielsen, C.J.; Ullman, D.R.; Norwood, J.A.; Thorne, G.D.; McCarthy, W.F.; Adams, R.C.; Rice, R.M.; Tang, D.; Berman, J.; Ransom, J.; Magill, A.J.; Grogl, M. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N. Engl. J. Med., 2013, 368(6), 524-532. [http://dx.doi.org/10.1056/NEJMoa1202657]. [PMID: 23388004].
[12]
Sosa, N.; Capitán, Z.; Nieto, J.; Nieto, M.; Calzada, J.; Paz, H.; Spadafora, C.; Kreishman-Deitrick, M.; Kopydlowski, K.; Ullman, D.; McCarthy, W.F.; Ransom, J.; Berman, J.; Scott, C.; Grogl, M. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am. J. Trop. Med. Hyg., 2013, 89(3), 557-563. [http://dx.doi.org/10.4269/ajtmh.12-0736]. [PMID: 23857024].
[13]
Miranda-Verástegui, C.; Llanos-Cuentas, A.; Arévalo, I.; Ward, B.J.; Matlashewski, G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis., 2005, 40(10), 1395-1403. [http://dx.doi.org/10.1086/429238]. [PMID: 15844060].
[14]
López, L.; Cruz, C.; Godoy, G.; Robledo, S.M.; Vélez, I.D. Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. Rev. Inst. Med. Trop. São Paulo, 2013, 55(3), S0036-46652013000300197. [http://dx.doi.org/10.1590/S0036-46652013000300011]. [PMID: 23740007].
[15]
López, L.; Robayo, M.; Vargas, M.; Vélez, I.D. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials, 2012, 13, 58. [http://dx.doi.org/10.1186/1745-6215-13-58]. [PMID: 22594858].
[16]
DNDi. 2019a.www.dndi.org/diseases-projects/portfolio/oxaborole-dndi-6148/ [(Accessed February 03, 2019)]
[17]
DNDi. 2019b.www.dndi.org/diseases-projects/portfolio/nitroimidazole/ [(Accessed February 04, 2019)]
[18]
DNDi. 2019c.www.dndi.org/diseases-projects/portfolio/dndi-5561/ [(Accessed February 04, 2019)]
[19]
DNDi. 2019d.www.dndi.org/diseases-projects/portfolio/cpg-d35/ [(Accessed February 04, 2019)]
[21]
Molina, I.; Gómez i Prat, J.; Salvador, F.; Treviño, B.; Sulleiro, E.; Serre, N.; Pou, D.; Roure, S.; Cabezos, J.; Valerio, L.; Blanco-Grau, A.; Sánchez-Montalvá, A.; Vidal, X.; Pahissa, A. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N. Engl. J. Med., 2014, 370(20), 1899-1908. [http://dx.doi.org/10.1056/NEJMoa1313122]. [PMID: 24827034].
[22]
Morillo, C.A.; Waskin, H.; Sosa-Estani, S.; Del Carmen Bangher, M.; Cuneo, C.; Milesi, R.; Mallagray, M.; Apt, W.; Beloscar, J.; Gascon, J.; Molina, I.; Echeverria, L.E.; Colombo, H.; Perez-Molina, J.A.; Wyss, F.; Meeks, B.; Bonilla, L.R.; Gao, P.; Wei, B.; McCarthy, M.; Yusuf, S. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS Trial. J. Am. Coll. Cardiol., 2017, 69(8), 939-947. [http://dx.doi.org/10.1016/j.jacc.2016.12.023]. [PMID: 28231946].
[23]
Torrico, F.; Gascon, J.; Ribeiro, I. E1224 - Results of proof of concept clinical trial in patients with chronic indeterminate Chagas disease. ASTMH 62nd Annual Meeting;Washington DC; Nov 13-17, 2013.
[24]
Kratz, J.M.; Garcia Bournissen, F.; Forsyth, C.J.; Sosa-Estani, S. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Rev. Clin. Pharmacol., 2018, 11(10), 943-957. [http://dx.doi.org/10.1080/17512433.2018.1509704]. [PMID: 30111183].
[25]
Sangenito, L.S.; Menna-Barreto, R.F.S.; d’Avila-Levy, C.M.; Branquinha, M.H.; Santos, A.L.S. Repositioning of HIV aspartyl peptidase inhibitors for combating the neglected human pathogen Trypanosoma cruzi. Curr. Med. Chem., in press


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [174 - 177]
Pages: 4
DOI: 10.2174/156802661903190328155136

Article Metrics

PDF: 45
HTML: 5